EquityZen Growth Technology Fund LLC - Series 736
Raised
$2M
Investors
52
Min Invest
$10,009
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 736 is a Delaware-organized pooled investment fund filed by EquityZen Advisors LLC that raised $2.3M from 52 investors under Rule 506(b), with a $10K minimum investment. This is an amended filing dated June 10, 2021, and is part of the EquityZen platform, which operates 1,891 related pre-IPO investment vehicles.
This pre-IPO fund represents a typical EquityZen series structure with a retail-accessible $10K minimum and Rule 506(b) exemption allowing general solicitation restrictions. The $44K average check size across 52 investors reflects the platform's model of democratizing access to private growth-stage equity through fractional pooled vehicles.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.